Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

fludarabine 9Cytarabine 9venetoclax 5fludarabine phosphate 5Cyclophosphamide 5Busulfan 5thymoglobulin 4Tacrolimus 4Sirolimus 4Mycophenolic Acid 4Methotrexate 4Azacitidine 4aldesleukin 3Whole-Body Irradiation 3Interleukin-2 3Antilymphocyte Serum 3asciminib 2Thiotepa 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Dasatinib 2Cyclosporine 2Bone Marrow Transplantation 2Blood Specimen Collection 2Behavior Therapy 2zileuton 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid × quizartinib × Clear all
NCT01411267 2022-04-04

AC220 for Children With Relapsed/Refractory ALL or AML

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Completed
24 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡